Introduction
Breast cancer, the most common cancer in women, is the primary cause of death amongst women in the United States [1] . However, the development of targeted biological therapies that down-regulate growth factor pathways is improving breast cancer prognosis for many women, particularly drugs like trastuzumab that target the human epithelial growth factor receptor (HER) family.
Intracellular signalling pathways are frequently up-regulated in cancer. Many well-established anti-cancer drugs block signalling via a particular pathway. However, due to cross talk and feedback mechanisms, inhibition of one signalling pathway can be compensated by up-regulation of another. The Phosphatidylinositol 3 kinase(PI3K)/protein kinase B (AKT) pathway, which is associated with growth, proliferation and survival [2] , is one of the most commonly upregulated signalling pathways in breast cancer. Signalling in the PI3K/AKT pathway is activated by PI3K catalysed conversion of phosphatidylinositoI-4,5-bisphosphate (PIP 2 ) to phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ). AKT activity is tightly controlled by the phosphatase, PTEN, which converts PIP 3 back to PIP 2 . Over-activation of PI3K/AKT signalling in cancer is a consequence of activating mutations of PI3K or AKT, deactivation of PTEN or overexpression of tyrosine kinase receptors which are upstream of PI3K/AKT [3] .
The HER family includes the EGFR (or HER1), and the target of trastuzumab, HER2 as well as HER3 and HER4. Ligand binding with HER1, three or four (HER2 is constitutively activated) permits interaction with another ligand-activated receptor member of the HER family forming homo-or hetero-dimers facilitating activation of intracellular tyrosine kinase domains. Activated dimers possess binding sites for components of the mitogen-activated protein kinase (ERK) and AKT signalling pathway e.g. PI3K, binding to which induces signalling through the PI3K/AKT pathway. Thus, HER3 has several PI3K binding sites and when it forms dimers with HER2 is a strong activator of PI3K [4] . HER2-overexpressing tumours consequently exhibit increased activity of downstream AKT.
Between 15 and 25 % of primary invasive breast cancers over-express HER2 which is indicative for treatment with the recombinant humanized monoclonal antibody trastuzumab. Whilst clinical benefit of trastuzumab to many patients with HER2-positive breast cancer is well established, less than 50 % [5] receiving trastuzumab as monotherapy respond and even when administered in the adjuvant setting 15 % of patients still relapse [6] . Trastuzumab is expensive and cardiotoxic [7] ; so early detection of nonresponders is a crucial requirement in oncology.
Positron [9, 10] .
However, rates of glucose utilisation do not necessarily correspond with activation levels of AKT [11] and response to HER-2-targeting drugs including trastuzumab which functions partly by inhibiting the AKT pathway have not consistently been shown to result in decreased [ 18 F]FDG incorporation [12, 13] . A number of factors confound the relationship between level of signalling pathway activation and downstream events; factors that include compensatory up-regulation of parallel signalling pathways e.g. inhibition of ERK increases AKT activity [14] . Further, the PI3K-AKT signalling pathway influences cell growth through anabolic processes that control glucose metabolism via hypoxia inducible factor 1a (HIF-1a) dependent and HIF1-independent mechanisms which may impact on how inhibition of AKT relates to [ 18 F]FDG incorporation.
The purpose of this study is to investigate the relative importance of AKT and ERK signalling inhibition in response to trastuzumab in cells growing under normoxic conditions, the role that the trastuzumab-induced inhibition of the pathways plays in inducing early changes in glucose transport and [
18 F]FDG incorporation and the involvement of HIF-1a in this process. Three cell lines BT474, MDA-MB-453 and SKBr3 which we have previously shown to be sensitive to trastuzumab [15] were employed. To demonstrate the relative insensitivity of these processes to trastuzumab in cells that do not overexpress HER2, MDA-MB-468, was also used.
Materials and chemicals
[ 18 F]FDG was synthesised by the University of Aberdeen's PET facility. LY294002 and U0126 were from Cambridge Biosciences (UK). Trastuzumab (Roche) was purchased from the Pharmacy at Aberdeen Royal Infirmary and used at a concentration of 5 lg/ml which is above that at which the growth inhibitory drug effect reaches a plateau [15] . All other chemicals were from Sigma-Aldrich (Poole UK) unless otherwise stated.
Cell culture
All cells were cultured in Dulbecco's Modified Eagle Medium (Gibco, Life Technologies Ltd, Paisley UK) supplemented with penicillin (100 U/ml) and streptomycin (100 lg/ml) and 10 % fetal bovine serum (Gibco). BT474, SKBr3 and MDA-MB-453 cell lines were purchased from the American Type Cell Collection. BT474 and MDA-MB-453 cells exhibit mutations in their PIK3CA genes whilst SKBr3 cells have wild-type PIK3CA [16] .
To determine cell sensitivity to PI3K inhibitor, LY294002 and ERK1/2 inhibitor U0126 cells were seeded (5,000 cells/well in 100 ll) in 96 well plates and exposed to 0.5-50 lM concentrations ± trastuzumab (5 lg/ml) for 72 h at 37°C. Medium then aspirated and 0.2 ml of MTT (10 %) in medium added per well then left at 37°C for 4 h then the MTT aspirated. DMSO (0.2 ml) was added to each well to dissolve the formazin crystals and absorbance read at 570 nm using a scanning multi-well spectrophotometer (Dynatech MR 5000, Dynatech Laboratories, Chantilly, VA, USA) after 30 s agitation. The readings were analysed using Ascent software. 6 cells per flask) in 5 ml of medium and allowed to incubate for 3 days at 37°C. One ml of medium-containing [ 18 F]FDG (37 KBq/ml) was administered to each flask. Incubation was continued for 20 min after which the medium was removed from the flasks and the cells washed 59 with PBS (5 ml). The cells were then detached by addition of 0.5 ml of trypsin (0.05 %)/EDTA (0.2 %) recovered into microfuge tubes and incorporated [
18 F]FDG measured using a well counter with a Nuclear Instruments (Oakland UK) interface until [1,000 counts accumulated. Cells were then centrifuged at 200 g for 5 min and the cells suspended in 100 ll of NaOH (1 M) and left overnight at 37°C. After neutralisation with 100 ll of HCL (1 M), a protein assay was carried out on the dissolved tissue. The 6 cells/60 mm plate and grown for 3 days. Cells were exposed to LY294002 (50 lM), trastuzumab (5 lg/ml) or LY294002 (50 lM) ? trastuzumab (5 lg/ml) for 4 h. Western blots were performed as described previously [17] . Antibodies were sourced from cell signalling (AKT, phospho Ser473 AKT, phospho Thr308 AKT, p44/42 ERK1/2, phospho Thr202/Tyr204 p44/ 42 ERK1/2), Insight Biotechnology (HER2/neu), DAKO (phospho-HER2) Becton-Dickinson (HIF1a) and Millipore (glut-1). Blotting was carried out two or three times in each case, and representative blots are shown.
Protein assay
Protein concentrations determined using the Bicinchoninic acid kit (Sigma-Aldrich UK) according to the manufacturer's instructions. Absorbance at 562 nm was measured on a Helios c (Thompson Spectronic) UV/Vis spectrophotometer.
Statistics
Significant differences between means were determined using the Student t test. All experiments were carried out at least three times.
Results
HER2 expression in the breast cancer cell lines was checked by western blotting. The results (Fig. 1a) demonstrated high levels of HER2 expression in BT474 and SKBr3 and medium levels in MDA-MB-453 cells and no detectable expression in MDA-MB-468 cells. This agrees with the literature [18] , confirming our cell lines have expected expression profiles. The phospho-HER2 level in MDA-MB-453 cells was lower than in BT474 and SKBr3 cells reflecting the lower level of HER-2 in MDA-MB-453 cells. Trastuzumab treatment decreased phospho-HER-2 expression in these three cell lines. Western blotting confirmed all three experimental cell lines contained AKT, pAKT, ERK1/2 and pERK1/2 (Fig. 1b, c) . AKT and pAKT protein levels were lower in SkBr3 cells compared with the other cell lines, but there was little difference in the intercellular ERK1/2 and pERK1/2 levels. Trastuzumab treatment had no detectable effect on ERK 1/2 phosphorylation (Fig. 1b) , but modestly decreased pAKT levels in all three HER-2 overexpressing cell lines (Fig. 1c) but not in HER-2 negative MDA-MB-468 cells (results not shown). Treatment of cells with LY294002 inhibited their growth (Fig. 2) . Trastuzumab (5 lg/ml) alone (initial point on each curve i.e. where LY294002 concentration is 0) inhibited the growth of each cell line by 30-40 %. In combination with trastuzumab (5 lg/ml), the growth inhibitory effect of LY294002 at concentrations of up to 5 lM was increased compared with LY294002 alone. However, the additive effect is not apparent at higher concentrations of LY294002. MDA-MB-468 cells did not show any decrease in cell number after treatment with trastuzumab (5 lg/ml) (results not shown).
To further investigate the relationship between PI3K/ AKT and trastuzumab, cells were treated with a high dose (50 lM) of the PI3K inhibitor LY294002. Inhibition of AKT reached a plateau with treatment of doses of LY294002 between 20 and 50 lM (results not shown). PI3K inhibitor treatment greatly decreased pAKT (Fig. 3a) in each cell line, but did not completely eliminate AKT phosphorylation of Thr308, presumably because phosphorylation is also maintained by other inputs [19] . Similar results obtained when Ser473 phosphorylation was studied (data not shown). Combination of LY294002 (50 lM) with trastuzumab did not further decrease pAKT levels suggesting that trastuzumab inhibition of pAKT is a consequence of its action via PI3K. Figure 3b shows the incorporation of [ (1-50 lM) was found to decrease in a dose-dependent manner (Fig 3c) . In contrast, no decrease It is well documented that ERK inhibition can cause upregulation of AKT phosphorylation [14] . Each cell line was treated for 4 h with the well-characterised ERK 1/2 inhibitor U0126 [20] . As expected, U0126 treatment eliminated all detectable pERK 1/2 in SKBr3 and BT474 cells (Fig. 4) . Strong pERK downregulation was also observed in MDA-MB-453 cells (Fig. 4) ; some residual pERK was observed in MDA-MB-453 cells, probably due to the very high-basal pERK levels. U0126 treatment caused a clear increase in pAKT and an upregulation of total ERK protein levels (Fig. 4) . U0126 was also found to inhibit the growth rate of MDA-MB-453, SKBr3 and BT474 cells (data not shown). [ 18 F]FDG incorporation was significantly increased in MDA-MB-453 and BT474 cells but not by SKBr3 cells (Fig. 4c) . HIF1a levels were undetectable in both the control and U0126-treated cells.
Glut-1 protein expression was not affected by any of the 4 h treatments (Fig. 3) . However, glucose transport is also controlled by several post-translational mechanisms, so glucose transport was examined at the functional level. The relative levels of glucose transport and the effect of AKT inhibition on glucose transport were determined in each cell line by measuring the rate of uptake of [ 3 H]O-methylglucose for the first 5 s after addition to the media. To be considered to be a measure of glucose transport it, the uptake of OMG must not reach equilibrium during the measurement period so uptake was also measured at 10 s for BT474 cells and was significantly (t = 4.95, p \ 0.01) higher than at 5 s (we have previously shown this to be the case for SKBr3, MDA-MB-453 and MDA-MB-468 cells [15] ). Figure 5a shows that whilst the rate of glucose transport is similar for BT474 and MDA-MB-453 cells, for SKBr3 cells, the rate is much greater. Treatment with LY294002 (50 lM) significantly) decreased glucose transport by each cell line corresponding with decreased 
Discussion
The AKT signalling pathway is associated with increases in hexokinase 2 activity, glucose transport and lactic acid production [11, 21, 22] , and constitutive up-regulation of AKT alone has been suggested to account for the switch to aerobic glycolysis exhibited by tumour cells [23] . Studies have shown that treatment of cancer cells with the HER-2 targeting antibody trastuzumab for 24 h [24] or 72 h [25] specifically decreases AKT but not ERK activation. A 4 h drug treatment time is considered as appropriate incubation period for drugs to target intracellular pathways [26] . Therefore, in this study, a 4 h drug treatment was employed to determine the early cell signalling associated effects of trastuzumab on glucose transport and [ 18 F]FDG incorporation, rather than the onset of growth inhibitory and cell death associated events exhibited at later time points. In common with studies using longer [25] incubation time decreases in pAKT levels, but not pEKR1/2, were observed after a 4 h treatment of HER-2-overexpressing breast cancer cells with trastuzumab.
Chan et al. [27] demonstrated that knockdown of Skp2, which regulates AKT ubiquitination, crucial in determining the membrane localisation, and hence activity of AKT, increases the sensitivity of cancer cells to trastuzumab, an effect countered by introduction of constitutively active AKT. They [27] also showed that AKT activation is a controlling pathway for glucose transporter expression.
In this study, glucose transport was significantly decreased by treatment with LY294002 in each cell line. The modest decrease in pAKT induced by trastuzumab suggests that trastuzumab is a relatively poor inhibitor of AKT phosphorylation as previously observed [24] . In contrast, the PI3K inhibitor LY294002 eliminated almost all detectable pAKT. Correspondingly, glucose transport was significantly inhibited by 50 lM LY294002, but the effect of trastuzumab on glucose transport was less apparent.
Although glucose transport (at the functional level) was decreased in SKBr3 cells by both trastuzumab and LY294002, treatment, neither agent decreased [
18 F]FDG incorporation in this cell line. A long exposure (72 h) to trastuzumab might be expected to change the pattern of [ 18 F]FDG incorporation due to later events associated with response such as the onset of cell death. However decreased [
18 F]FDG incorporation was evident in both BT474 and MDA-MB-453 cells suggesting that it's not a short-term phenomenon. Palaskas et al. [28] showed that PTEN knockdown in SKBr3 cells, which results in high [29, 30] . Growth factor withdrawal results in a rapid decrease in cell surface glucose transporter expression [29, 30] (within hours). Therefore, [ 18 F]FDG incorporation may be unaffected by AKT inhibition in cancer cells, such as SKBr3 cells in which glucose transport is very high.
Although some studies suggest that decreased [ 18 F]FDG incorporation predicts response of breast tumours [31] and xenografts [32, 33] derived from breast cancer cells, to anti-HER2 treatments, the results from a xenograft study [12] [34] showed that treatment of BT474 cells with the PI3K inhibitor AZD5363 inhibited growth of xenografts derived from BT474 cells and decreased FDG incorporation after 4 h treatment.
In some cells in normoxic conditions, HIF-1a is involved in the enhanced glycolysis in tumour cells due to its activation by intracellular signalling pathways including PI3K/AKT [35, 36] . Inhibition of PI3K/AKT in some tumour types including thyroid [37] and prostate cancer [38] can result in HIF1a down-regulation, and this can act as a mediator of the downstream effects of AKT de-activation [38, 39] . However, the role of HIF1a in controlling tumour cell glucose utilisation as a function of AKT activation in normoxia is tumour type-dependent. Studies using leukaemic [23] and human bladder cancer cells [40] have shown that up-regulation of AKT does not necessarily result in up-regulation of HIF1a expression or of HIF1a target genes including that of GLUT1.
In the three breast cancer cell lines in the present study which was carried out under normoxic conditions, the downstream effects of AKT inhibition on glucose transport and [
18 F]FDG incorporation did not appear to be routed through HIF1a. HIF1a protein expression was undetectable in all three cell lines and administration of YC1 to MDA-MB-453 cells at a dose that strongly down-regulates HIF1a levels [17] ERK inhibitors are being explored for the treatment of a variety of ras-activated cancer types. Compensatory changes in AKT activation during treatment with ERK inhibitors have been observed [14] . We found that inhibition of ERK with U0126 which was growth inhibitory in each cell line actually increased [ 18 F]FDG incorporation in two cell lines due to an increase in pAKT levels. Inhibition of ERK increases AKT activity and [
18 F]FDG incorporation and is a potential source of metabolic flare associated with some anti-cancer treatment.
The findings of the present study suggest that inhibition of AKT in normoxic cells can result in early changes in [ 18 F]FDG incorporation and that this is independent of HIF-1a. However, a number of factors are involved which include the decrease in pAKT levels below a threshold level at least in some cancers before glucose transport is appreciably affected and that glucose transport may need to be a rate limiting factor in [
18 F]FDG incorporation in that cell line. This may account for the variation in preclinical and clinical findings associated with [
18 F]FDG-PET in response to trastuzumab and other HER-2 targeting drugs [12, 13, [32] [33] [34] .
